Using its Artificial Intelligence platform KEM®, Ariana integrates gut microbiota data with clinical and omic parameters enabling extensive patient stratification strategies. Use of Artificial Intelligence allows applying this technology as early as the preclinical steps (animal models) and early development phases (I and II) with limited number of patients.
Although, there is growing evidence in a broad range of therapeutic areas such as cancer, CNS, metabolic diseases etc., for the key importance of human microbiota modulating response to therapy, the sheer size and complexity of the data produced, corresponding to a large number of different bacteria and their hierarchical taxonomic organization, has hindered until now their use in clinical trials.
At Ariana, we have developed an Artificial Intelligence platform KEM® that enables the integration and analysis of very “wide” data such as gut microbiota 16S and shotgun, even for small number of patients, identifying clinically actionable biomarkers. We have a track record of successfully applying our technology across multiple therapeutic areas.
Ariana Pharma is a leading digital health Company focused on developing advanced therapeutic decision support systems. Using its KEM® Explainable Artificial Intelligence (XAI) technology, Ariana helps its partners introduce precision medicine clinical trial design into their protocols and identify best clinical endpoints, best responders and best potential synergistic drugs. Ariana routinely collects and combines complex, heterogeneous data from clinical trials, observational studies or Real World Evidence to help its partners translate findings into innovative clinical plans.